Biognosys is the world leader in the application of next-generation proteomics solutions to accelerate your research and drug development timelines.

From basic research to early drug discovery and late-stage clinical development, Biognosys’ proteomics solutions can provide key insights into cancer disease biology and reveal the mechanism of action of novel therapeutics.

Gaining deeper functional knowledge of how therapy or disease alters the proteome can lead to the identification of proteomic signatures that act as biomarkers to monitor or predict response to therapy and anticipate adverse events, ultimately reducing the risk of failure in drug development.

Here are a few examples of how we have applied proteomics to address key questions in cancer drug discovery and development:


Target Discovery

Global proteomic profiling of tumors to identify novel therapeutic targets

Biognosys’ proteomics workflows enable the identification of dysregulated proteins in disease, revealing deep insights into cancer biology and new targets for further exploration.

Biognosys’ Discovery Proteomics approach was used to deeply characterize global tumor proteomes from melanoma FFPE sections to uncover proteins and pathways implicated in the disease, highlighting potential novel therapeutic targets.


Case Study: Novel Target Discovery in Melanoma                

Application: Biomarker Discovery

Mechanism of Action

Profiling of the proteomic response to therapy in animal models

Proteomic profiling of tissue or tumor samples from animal models of disease reveals detailed information about the proteins and pathways involved in response to therapy.

For example, Biognosys’ Discovery Proteomics was used to investigate the role of immune cell depletion in the response to PD-1 blockade in syngeneic mouse models.


Case study: Mechanism of Action of Immunotherapy in Syngeneic Mouse Models

Application: Mechanism of Action Studies

Small Molecule Target Deconvolution

Proteome-wide characterization of the binding specificity and selectivity of small molecules

Biognosys’ drug Target Deconvolution approach Limited Proteomics Mass Spectrometry (LiP-MS) can effectively identify protein drug targets and characterize their binding properties in complex proteomes without the need for compound modification or labeling.

In this specific example, LiP-MS was used to distinguish the specificity and selectivity of different kinase and phosphatase inhibitors.


Case Study: Target Deconvolution of Drug Specificity and Selectivity

Publication: A machine-learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes (Nature Communications, 2020)

Technology Video: LiP-MS: A Novel Target Deconvolution Approach

Application: Target Deconvolution


«The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.»

Thomas Knoblauch
Laboratory Manager, Bayer

Blood-based Biomarker Discovery

Deep proteomics characterization of biofluids

Biognosys’ Discovery Proteomics approach offers a highly reproducible and scalable workflow for analyzing biofluids such as blood plasma or serum, making it the ideal choice for your biomarker research needs.

Our plasma/serum workflow enables robust and reproducible quantification of 600+ proteins in plasma or serum samples across large-scale studies. The use of our proprietary reference kit PQ500 enables the absolute quantification of up to 500 proteins in human plasma or serum.

For deeper profiling and exploration of lower abundant proteins, we have developed a workflow that depletes samples of the most common plasma proteins to reveal the less abundant informative molecules, allowing the quantification of 1’000+ proteins. 

Browse the case studies below to see the power of our blood-based proteomics workflows to identify novel biomarkers associated with disease progression and response to therapy in lung cancer.


Case Study: Plasma Proteome Profiling and Clinical Outcome Association in Subjects with NSCLC

Product Brochure: PQ500: The Key to the Plasma Proteome

Application: Biomarker Discovery

Phosphorylation Profiling

Profiling of phosphorylation sites in the cancer proteome

The discovery proteomics approach offers a scalable workflow to reliably and reproducibly profile thousands of samples from multiple time points, making it the ideal choice for clinical biomarker studies.

In partnership with Indivumed, we have developed a high-throughput Discovery Proteomics workflow for the acquisition of large-scale deep proteomics and phospho-proteomics datasets from a longitudinal cohort of matching fresh-frozen tumor and adjacent healthy tissue samples from thousands of cancer patients. The data is being used to enrich Indivumed’s unique collection of biobank specimens.


Poster: Large Scale Phospho Proteomics of Tumor Tissues

Press Release: Indivumed Announces Strategic Partnership with Biognosys

Video: Oliver Rinner (Biognosys CEO) Speaks about Strategic Partnership with Indivumed


Let us help you do great proteomics!

Please click here to contact us.